PSMD1-score | 1 (n=29) | 2 (n=26) | 3 (n=27) |
---|---|---|---|
Age (years) mean | 59.5 | 62.1 | 59.3 |
Q1/Q2/Q3 | 54/59/65 | 56/61.5/69.7 | 55/60/63 |
Male (%) | 96.5 | 84.6 | 92.5 |
Weight (kg) mean | 72.7 | 72.0 | 71.7 |
Q1/Q2/Q3 | 60/67/81 | 61.5/66/79 | 64.5/72/80 |
Smoker (n) | 17/26 | 19/24 | 20/26 |
Karnofski >= 70 (n) | 11/13 | 8/8 | 6/7 |
Hemoglobin level (mg/dL) mean | 12.7 | 13.5 | 13.2 |
Q1/Q2/Q3 | 11.9/12.9/14 | 12.8/13.7/14.1 | 12.4/13.5/14.4 |
Oral cavity n (%) | 4 (13.7) | 3 (11.5) | 5 (18.5) |
Oropharynx n (%) | 13 (44.8) | 9 (34.5) | 9 (33.3) |
Hypopharynx n (%) | 10 (34.4) | 11 (42.2) | 8 (29.6) |
Larynx n (%) | 2 (6.8) | 3 (11.5) | 5 (18.5) |
cT1 n (%) | 1 (3.4) | 1 (3.8) | Â |
cT2 n (%) | 2 (6.8) | 3 (11.5) | 4 (14.8) |
cT3 n (%) | 11 (37.9) | 6 (23.0) | 7 (25.9) |
cT4 n (%) | 15 (51.7) | 16 (61.5) | 16 (59.2) |
cN0 n (%) | 2 (6.8) | 4 (15.3) | 3 (11.1) |
cN1 n (%) | 6 (20.6) | 1 (3.8) | 1 (3.7) |
cN2 n (%) | 19 (65.3) | 20 (76.8) | 21 (57.7) |
cN3 n (%) | 2 (6.9) | 1 (3.8) | 2 (7.4) |
G1 n (%) | 2 (6.8) | 2 (7.6) | Â |
G2 n (%) | 12 (41.3) | 17 (65.3) | 14 (53.8) |
G3 n (%) | 15 (51.7) | 7 (26.9) | 12 (46.1) |
EpoR (C20+) (%) | 19 (65.5) | 18 (69.2) | 22 (81.4) |
RT (Gy) mean | 71.1 | 69.7 | 67.7 |
Q1/Q2/Q3 | 70/70.6/72 | 69.9/70/70.6 | 70/70/70.6 |
RT (days) | 48.1 | 47.5 | 45.0 |
Q1/Q2/Q3 | 42.5/48/52 | 42/45.5/51 | 42/45/50 |
treated in study A1/B2/C3/D4 (n) | 1/10/14/4 | 3/10/7/6 | 4/13/6/4 |
Local control (months) median | 18.3 | nr | nr |
Survival (months) median; 95% CI | 21.2; 10.5-28.7 | 28.8; 6.3-42.4 | 43.8; 12.4- |